Chargement en cours...
Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials
AIM: To assess the effect of empagliflozin on cardiovascular (CV) risk in patients with type 2 diabetes (T2DM) through a meta‐analysis of data from eight placebo‐controlled trials. METHODS: Data were analysed from eight randomized placebo‐controlled trials undertaken to investigate the efficacy and...
Enregistré dans:
| Publié dans: | Diabetes Obes Metab |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Blackwell Publishing Ltd
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5096016/ https://ncbi.nlm.nih.gov/pubmed/27376831 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12734 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|